Tonix Pharmaceuticals is currently enrolling participants in a Phase 3 trial for posttraumatic stress disorder (PTSD). For more information, please visit www.recoverystudy.com or www.clinicaltrials.gov (NCT03841773).

News / Press Releases

: Press Releases

Press Releases

Tonix Pharmaceuticals Completes Enrollment in Phase 2 Clinical Trial of TNX-102 SL in Post-Traumatic Stress Disorder (PTSD)

December 23, 2015 • 7:00 AM EST

Tonix Pharmaceuticals Completes Enrollment in Phase 2 Clinical Study of TNX-201 in Episodic Tension-Type Headache

December 8, 2015 • 7:00 AM EST

Tonix Pharmaceuticals and U.S. Department of Defense Military Developer in Partnership to Expand Efforts to Examine TNX-102 SL for Post-Traumatic Stress Disorder

December 7, 2015 • 7:00 AM EST

Tonix Pharmaceuticals to Participate in Fireside Chat at the Oppenheimer 26th Annual Healthcare Conference

December 1, 2015 • 7:00 AM EST

Tonix Pharmaceuticals Presents Additional Data on Tonmya(TM) Demonstrating Improvements in Sleep, Pain, and Other Outcomes in Fibromyalgia at 2015 ACR/ARHP Annual Meeting

November 10, 2015 • 8:30 AM EST

Tonix Pharmaceuticals Reports Third Quarter 2015 Financial Results and Provides Programs Update

November 9, 2015 • 7:00 AM EST

Tonix Pharmaceuticals Announces Acceptance of Three Abstracts to be Presented at the 2015 ACR/ARHP Annual Meeting

October 1, 2015 • 7:00 AM EDT

Tonix Pharmaceuticals to Present at the 15th Annual Biotech in Europe Forum for Global Partnering and Investment

September 24, 2015 • 7:00 AM EDT

Tonix Pharmaceuticals to Present at the Rodman & Renshaw Global Investment Conference

September 8, 2015 • 7:05 AM EDT

Tonix Pharmaceuticals Presents on the Development of TNX-102 SL for Post-Traumatic Stress Disorder (PTSD) at the 2015 Military Health System Research Symposium

August 18, 2015 • 1:00 PM EDT

Show All

News / Press Releases : Press Releases